STRO
Sutro Biopharma, Inc.NASDAQHealthcare$23.78-4.38%ClosedMarket Cap: $202.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.55
P/S
1.99
EV/EBITDA
-3.14
DCF Value
$-103.41
FCF Yield
-87.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.4%
Operating Margin
-150.2%
Net Margin
-186.5%
ROE
275.3%
ROA
-109.9%
ROIC
-144.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $11.6M | 86.1% | $-33.7M | $-46.8M | $-5.45 | — |
| FY 2025 | $102.5M | 92.9% | $-105.0M | $-191.1M | $-22.49 | — |
| Q3 2025 | $9.7M | 100.0% | $-48.5M | $-56.9M | $-6.70 | — |
| Q2 2025 | $63.7M | 100.0% | $-3.3M | $-11.5M | $-1.40 | — |
| Q1 2025 | $17.4M | 100.0% | $-68.5M | $-76.0M | $-9.10 | — |
| Q4 2024 | $14.8M | 100.0% | $-65.3M | $-72.4M | $-8.80 | — |
| FY 2024 | $62.0M | 88.4% | $-238.5M | $-227.5M | $-29.60 | — |
| Q3 2024 | $8.5M | 100.0% | $-67.9M | $-48.8M | $-5.90 | — |
| Q2 2024 | $25.7M | 93.0% | $-48.7M | $-48.0M | $-5.90 | — |
| Q1 2024 | $13.0M | 86.5% | $-56.6M | $-58.2M | $-9.50 | — |
| Q4 2023 | $113.7M | 100.0% | $43.2M | $31.1M | $5.10 | — |
| FY 2023 | $153.7M | 95.6% | $-89.3M | $-106.8M | $-17.80 | — |